Has Meredith McKean, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,020,358 in general payments to Meredith McKean, MD across 3,702 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Meredith McKean, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Meredith McKean, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Meredith McKean, MD

Hematology & Oncology · Nashville, TNNPI 1437425659

Payments from drug & device makers

$16,020,358in general payments, 2019–2025

Across 3,702 payments — averaging $4327.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$2.2M
Merck$2.2M
Regeneron$1.9M
Sanofi US Services Inc.$1.3M
Daiichi Sankyo Inc.$1.2M
Seagen Inc.$927K
plus $6.3M from 54 others

$37,031in research payments, 2019–2025

Across 86 payments — averaging $430.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$21K
Regeneron$14K
F. Hoffmann-la Roche AG$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	222	$2,237,774
Merck	63	$2,169,217
Regeneron	653	$1,891,423
Sanofi US Services Inc.	204	$1,306,326
Daiichi Sankyo Inc.	778	$1,185,736
Seagen Inc.	205	$927,097
Genentech, Inc.	203	$859,421
Novartis	55	$774,105
Biontech SE	213	$640,758
GSK	109	$595,460
Modernatx, Inc.	134	$572,087
Iovance Biotherapeutics, Inc.	44	$354,523
Epizyme, Inc.	93	$295,601
AstraZeneca(2 entities)	24	$267,106
G1 Therapeutics, Inc.	156	$259,644
E.r. Squibb & Sons, L.L.C.	30	$230,448
Teva Pharmaceuticals USA, Inc.	34	$212,625
Exelixis Inc.	70	$187,179
Aadi Bioscience, Inc.	30	$161,594
EMD Serono, Inc.	21	$160,720
Synthorx Inc.	17	$120,408
Boehringer Ingelheim	19	$112,604
Amgen	12	$107,231
Ipsen Pharma SAS	42	$104,472
Merck Kgaa	13	$86,720
Takeda Pharmaceuticals U.S.A., Inc.	38	$70,575
Bayer	12	$37,049
Astrazeneca UK Limited	6	$32,750
Gilead	10	$21,911
Regeneron Healthcare Solutions, Inc.	52	$12,785
F. Hoffmann-la Roche AG	5	$10,808
Array Biopharma Inc	11	$4,551
Astellas Pharma Global Development	1	$2,180
Eisai Inc.	7	$1,914
Boehringer Ingelheim Pharma GmbH & Co.kg	7	$1,580
Boehringer Ingelheim International GmbH	13	$1,184
Immunocore Limited	8	$649
Delcath Systems	2	$272
Genentech USA, Inc.	6	$191
Springworks Therapeutics, Inc.	5	$114
Lilly USA, LLC	5	$96
Johnson & Johnson	5	$96
Servier Pharmaceuticals LLC	4	$87
Stemline Therapeutics Inc.	4	$86
Sanofi	2	$73
Jazz Pharmaceuticals Inc.	3	$69
Beone Medicines USA, Inc.	3	$64
Pharmacyclics LLC, An Abbvie Company	3	$61
Taiho Oncology, Inc.	3	$56
Incyte Corporation	2	$51
Tersera Therapeutics LLC	3	$51
Astellas Pharma US Inc	2	$50
Caris MPI, Inc.	3	$47
Tempus AI, Inc	2	$47
Beigene USA, Inc.	2	$47
Avyxa Pharma, LLC	2	$46
AVEO Pharmaceuticals, Inc.	1	$44
Bristol Myers Squibb	2	$43
Mirati Therapeutics, Inc.	2	$39
Rigel Pharmaceuticals, Inc.	2	$37

How this compares

$16,020,358 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$1,695,126

Medicare patients

301

Services billed

43,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nashville

Erika HamiltonNashville$45.4M
Ian FlinnNashville$41.2M
Johanna BendellNashville$28.5M
Jesus BerdejaNashville$22.2M
Krish PatelNashville$14.2M
Denise YardleyNashville$13.2M
Todd BauerNashville$10.9M
Wade IamsNashville$8.9M
Benjamin GarmezyNashville$8.4M
Brian RiniNashville$8.1M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →